Rankings
▼
Calendar
RYTM Q1 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RYTM
Rhythm Pharmaceuticals, Inc.
$6B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$11M
+665.6% YoY
Gross Profit
$10M
87.6% margin
Operating Income
-$53M
-458.0% margin
Net Income
-$52M
-455.0% margin
EPS (Diluted)
$-0.91
QoQ Revenue Growth
+30.5%
Cash Flow
Operating Cash Flow
-$36M
Free Cash Flow
-$36M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$346M
Total Liabilities
$126M
Stockholders' Equity
$220M
Cash & Equivalents
$110M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$11M
$1M
+665.6%
Gross Profit
$10M
$1M
+692.4%
Operating Income
-$53M
-$53M
+0.3%
Net Income
-$52M
-$53M
+1.1%
← FY 2023
All Quarters
Q2 2023 →